SCHEMBL1746749

SCHEMBL1746749

Fc1cc(Br)cc(F)c1OC1CCc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.49
SLC6A4 P31645 5/20 0.39
PIN1 Q13526 1/20 0.36
FFAR1 O14842 3/20 0.36
PDPK1 O15530 1/20 0.35
GPR84 Q9NQS5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12320178 0.88 IDO1 (0.51) IDO1SLC6A4PIN1FFAR1PDPK1
SCHEMBL12320500 0.85 IDO1 (0.45) IDO1SLC6A4PIN1FFAR1PDPK1
SCHEMBL12320177 0.80 IDO1 (0.46) IDO1SLC6A4PIN1FFAR1PDPK1
SCHEMBL1745236 0.77 AKR1C3 (0.40) IDO1PIN1FFAR1
SCHEMBL4261410 0.76 CCR2 (0.42) IDO1PIN1FFAR1
SCHEMBL4261413 0.76 CCR2 (0.42) IDO1PIN1FFAR1
SCHEMBL1746491 0.76 FFAR1 (0.43) IDO1PIN1FFAR1
SCHEMBL31360588 0.75 IDO1 (0.50) IDO1SLC6A4FFAR1
SCHEMBL12320173 0.74 SLC6A4 (0.51) IDO1SLC6A4PIN1
SCHEMBL1745233 0.74 FFAR1 (0.40) IDO1PIN1FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1688138-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2006-08-09 EP disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167378-A1 Receptor Function Regulation Agent GPR119, INSR, GPR88 IDO1 4552/4885SLC6A4 1453/4885PIN1 4678/4885
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR IDO1 3107/4885SLC6A4 847/4885PIN1 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.